Vifor Pharma AG Stock
28.06.19 / Tradegate
WKN: A2DRZ4 / Name: Vifor Pharma / Stock / Pharmaceuticals / Mid Cap
Your prediction
Vifor Pharma AG Stock
There is an upward development for Vifor Pharma AG compared to yesterday, with an increase of €0.000 (2.670%).
Pros and Cons of Vifor Pharma AG in the next few years
Pros
?
Shareholder structure
?
Conscious of the environment
?
Worthwhile Investment for the next years
Cons
?
Market Position
?
Brand
?
Growth compared to competition
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vifor Pharma AG vs. its peers
| Security | Change (%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vifor Pharma AG | 2.670% | - | - | - | - | - | - |
| Almirall S.A. | 1.210% | 6.667% | 3.822% | -6.034% | 5.036% | - | - |
| Swedish Orphan Biovitrum Ab | 0.320% | -0.108% | -15.841% | -7.114% | -15.222% | 0.181% | - |
| Dr. Reddy's Laboratories Ltd. ADR | 0.990% | 2.410% | -6.422% | 37.097% | -9.735% | 90.512% | 17.552% |
Other discussions about Vifor Pharma AG Stock
New thread ForumNews
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/
Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1
Regulatory News:
Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques